Roche's Ventana Licenses p63 Technology to Biocare
February 26, 2013
Roche's Ventana Licenses p63 Technology to Biocare
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Cell Signaling Technology, Ventana Ink Deal for EGFR Detection Technology
March 15, 2011 / GenomeWeb Daily News - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - Ventana Sublicensing IP from Gen-Probe for ERG Protein Measurement
May 21, 2012 / GenomeWeb Daily News - Ventana Developing CDx for Seattle Genetics, Millenium Cancer Drug
April 12, 2012 / GenomeWeb Daily News - Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter